{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:14:54Z","timestamp":1770333294932,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD085887"],"award-info":[{"award-number":["R01 HD085887"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.contraception.2023.109975","type":"journal-article","created":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T01:16:55Z","timestamp":1676164615000},"page":"109975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study"],"prefix":"10.1016","volume":"122","author":[{"given":"Lauren R.","family":"Cirrincione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadia","family":"Nakalema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Byakika-Kibwika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Kyohairwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope","family":"Mackline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2023.109975_bib1","series-title":"Adding it up: costs and benefits of contraceptive services - estimates for 2012","author":"Singh","year":"2012"},{"key":"10.1016\/j.contraception.2023.109975_bib2","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS). Fact sheet 2022. UNAIDS 2022 epidemiological estimates; 2022. Available from: \u3008https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf\u3009 (cited Aug 1, 2022)."},{"key":"10.1016\/j.contraception.2023.109975_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bpobgyn.2019.12.002","article-title":"Long-acting reversible contraceptive (LARCs) methods","volume":"66","author":"Bahamondes","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2023.109975_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12978-019-0713-x","article-title":"Availability of integrated family planning services in HIV care and support sites in sub-Saharan Africa: a secondary analysis of national health facility surveys","volume":"16","author":"Kanyangarara","year":"2019","journal-title":"Reprod Health"},{"key":"10.1016\/j.contraception.2023.109975_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.contraception.2021.08.006","article-title":"Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens","volume":"105","author":"Kreitchmann","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/cid\/civ1001","article-title":"Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks","volume":"62","author":"Scarsi","year":"2016","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.contraception.2023.109975_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2023.109975_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2020.100027","article-title":"Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30\u00a0months of concomitant use: a subanalysis of a randomized clinical trial","volume":"2","author":"Tang","year":"2020","journal-title":"Contracept X"},{"key":"10.1016\/j.contraception.2023.109975_bib9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/QAD.0000000000002308","article-title":"A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda","volume":"33","author":"Patel","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2023.109975_bib10","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2023.109975_bib11","unstructured":"Jadelle. [package insert]. Auckland, New Zealand: Bayer New Zealand Limited Company; Sept 2020. \u3008https:\/\/www.medsafe.govt.nz\/profs\/datasheet\/j\/jadelleimplant.pdf\u3009."},{"key":"10.1016\/j.contraception.2023.109975_bib12","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/jac\/dkac296","article-title":"Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy","volume":"77","author":"Nakalema","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.contraception.2023.109975_bib13","series-title":"Medical eligibility criteria for contraceptive use","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.contraception.2023.109975_bib14","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.contraception.2023.109975_bib15","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2022"},{"key":"10.1016\/j.contraception.2023.109975_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0015-0282(98)00015-6","article-title":"Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant","volume":"69","author":"Makarainen","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2023.109975_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0002-9378(97)70520-9","article-title":"Single luteal phase serum progesterone assay as an indicator of ovulation","volume":"176","author":"Israel","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2023.109975_bib18","unstructured":"Division of AIDS. National Institute of Allergy and Infectious Diseases. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. National Institutes of Health, U.S. Department of Health and Human Services; 2017. Available from: \u3008https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf\u3009 (cited July 4, 2022)."},{"key":"10.1016\/j.contraception.2023.109975_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchromb.2018.03.023","article-title":"Development, validation and utilization of a highly sensitive LC-MS\/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma","volume":"1084","author":"Cirrincione","year":"2018","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.contraception.2023.109975_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0010-7824(96)00276-4","article-title":"Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants","volume":"55","author":"Sivin","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib21","series-title":"Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions","author":"Center for Drug Evaluation and Research (CDER)","year":"2020"},{"key":"10.1016\/j.contraception.2023.109975_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2023.109975_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.contraception.2016.03.006","article-title":"Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing","volume":"94","author":"Edelman","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109951","article-title":"Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens","author":"Scarsi","year":"2023","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib25","doi-asserted-by":"crossref","first-page":"E610","DOI":"10.1210\/jc.2012-3195","article-title":"Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS)","volume":"98","author":"Karim","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2023.109975_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cpt.667","article-title":"The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine","volume":"102","author":"Neary","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.109975_bib27","first-page":"307","article-title":"Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants","volume":"101","author":"Croxatto","year":"1982","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.contraception.2023.109975_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0010-7824(90)90145-L","article-title":"Ovarian endocrine function through five years of continuous treatment with NORPLANT\u00ae subdermal contraceptive implants","volume":"41","author":"Brache","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.contraception.2016.03.010","article-title":"The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy","volume":"94","author":"Cherala","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109975_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/jac\/dkx515","article-title":"Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART","volume":"73","author":"Roberts","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:22:42Z","timestamp":1757881362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782423000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"alternative-id":["S0010782423000355"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2023.109975","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2023.109975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109975"}}